The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial.
Level 5 - mechanism / opinion, no new human data
Clinical trial protocol containing no outcome data
PubMed 29720225 · doi:10.1186/s13063-018-2637-0
What was done
This protocol describes a 12-week, 5-arm exploratory randomized controlled trial designed to evaluate the role of interleukin-6 (IL-6) in exercise-induced fat loss. The study planned to recruit 75 physically inactive adults (aged >18 years) with abdominal obesity (waist-to-height ratio > 0.5 and/or waist circumference ≥ 88 cm for females, ≥ 102 cm for males). Participants are randomly assigned (1:1:1:1:1) to: endurance exercise with tocilizumab (ET), endurance exercise with saline placebo (EP), no exercise with tocilizumab (NT), no exercise with placebo (NP), or resistance exercise with placebo (RP). The primary outcome is change in visceral adipose tissue (VAT) volume measured by magnetic resonance imaging (MRI). Secondary outcomes include epicardial and pericardial adipose tissue volumes (MRI), and gastric emptying and glucose metabolism (mixed-meal tolerance tests).
What was found
The abstract reports no results or numerical data because it is a trial protocol description.
Why it matters
Determining whether IL-6 acts as an essential mediator of exercise-induced visceral and epicardial fat loss could clarify the biological mechanisms driving exercise-related cardiometabolic protection.
Limits
This paper contains only the study protocol and provides no experimental or clinical results. The planned sample size of 75 participants across five arms results in small cell sizes (~15 per arm), limiting statistical power for subgroup or secondary metabolic analyses. The intervention is limited to 12 weeks.
Cited by
- supports A waist circumference of 35 inches or above in women and 40 inches or above in men is clinically used as a proxy threshold for high visceral fat.